Next Issue
Previous Issue

Table of Contents

Antibodies, Volume 3, Issue 4 (December 2014), Pages 272-302

  • Issues are regarded as officially published after their release is announced to the table of contents alert mailing list.
  • You may sign up for e-mail alerts to receive table of contents of newly released issues.
  • PDF is the official format for papers published in both, html and pdf forms. To view the papers in pdf format, click on the "PDF Full-text" link, and use the free Adobe Readerexternal link to open them.
View options order results:
result details:
Displaying articles 1-2
Export citation of selected articles as:
Open AccessReview Antibody Fragments Defining Biologically Relevant Conformations of Target Proteins
Antibodies 2014, 3(4), 289-302; https://doi.org/10.3390/antib3040289
Received: 10 November 2014 / Revised: 2 December 2014 / Accepted: 8 December 2014 / Published: 11 December 2014
Cited by 1 | PDF Full-text (830 KB) | HTML Full-text | XML Full-text
Abstract
Antibody fragments have long been used as chaperones in crystallography, but have more recently been applied to the definition of biologically relevant conformations among the dynamic ensemble of target protein conformational sampling. This review charts the progress being made in understanding function in
[...] Read more.
Antibody fragments have long been used as chaperones in crystallography, but have more recently been applied to the definition of biologically relevant conformations among the dynamic ensemble of target protein conformational sampling. This review charts the progress being made in understanding function in the context of structure using this approach, and highlights new opportunities for drug discovery. Full article
(This article belongs to the Special Issue Antibody Constructs)
Figures

Figure 1

Open AccessArticle Polyclonal Antibody Therapies for Clostridium difficile Infection
Antibodies 2014, 3(4), 272-288; https://doi.org/10.3390/antib3040272
Received: 26 August 2014 / Revised: 18 September 2014 / Accepted: 28 September 2014 / Published: 28 October 2014
Cited by 1 | PDF Full-text (2869 KB) | HTML Full-text | XML Full-text
Abstract
Clostridium difficile infection has emerged as a growing worldwide health problem. The colitis of Clostridium difficile infection results from the synergistic action of C. difficile secreted toxins A and B upon the colon mucosa. A human monoclonal IgG anti-toxin has demonstrated the ability
[...] Read more.
Clostridium difficile infection has emerged as a growing worldwide health problem. The colitis of Clostridium difficile infection results from the synergistic action of C. difficile secreted toxins A and B upon the colon mucosa. A human monoclonal IgG anti-toxin has demonstrated the ability in combination therapy to reduce mortality in C. difficile challenged hamsters. This antibody is currently in a clinical trial for the treatment of human Clostridium difficile infection. More than one group of investigators has considered using polyclonal bovine colostral antibodies to toxins A and B as an oral passive immunization. A significant proportion of the healthy human population possesses polyclonal antibodies to the Clostridium difficile toxins. We have demonstrated that polyclonal IgA derived from the pooled plasma of healthy donors possesses specificity to toxins A and B and can neutralize these toxins in a cell-based assay. This suggests that secretory IgA prepared from such pooled plasma IgA may be able to be used as an oral treatment for Clostridium difficile infection. Full article
(This article belongs to the Special Issue Antibodies Therapies against Infectious Diseases)
Figures

Figure 1

Back to Top